Advantages of the combined therapy with metformin and glimepiride in patients with type 2 diabetes mellitus

V.I. Pankiv

Abstract


Background. The use of glimepiride in the therapy of type 2 diabetes mellitus (DM) fewer stimulates the pancreas, keeping its resource, and does not result in hyperinsulinemia, and also provides the highest profile of safety at the lowest stimulation effect on the secretion of insulin. A research aim is determination of efficiency and safety of a combination of metformin and glimepiride during its application in clinical practice for patients with type 2 DM and the level of glycated hemoglobin (HbA1c) 8.5–9.5 %. Materials and methods. Under supervision, there were 29 patients with type 2 DM (duration of the disease was 8.7 ± 3.2 years). Patients were in the state of DM decompensation on a background of therapy with metformin and long acting glyclazide in maximal doses during at least previous three months. Patients received metformin and glimepiride. The initial dose for all patients with type 2 DM was 2,500 mg of metformin and 4 mg of glimepiride. Results. In 3 months after the initial stage, the level of HbA1c significantly decreased — from 9.02 ± 0.41 % to 7.53 ± 0.48 % (p < 0.05). The average reduction in HbA1c after transition to therapy with metformin and glimepiride was 1.49 ± 0.42 %. Efficiency of the additional administration of glimepiride is also confirmed by the high percentage of patients, who achieved the level of HbA1c < 7.0 %, — 13.8 % (p < 0.05). The level of fasting glycaemia decreased from 10.18 ± 1.32 mmol/l to 7.02 ± 1.08 mmol/l in 3 months. The decline achieved 3.07 ± 1.06 mmol/l that in relative expression was –31.2 ± 9.4 % from an initial value. The level of postprandial glycaemia reduced from 11.8 ± 2.14 mmol/l initially to 8.16 ± 1.02 mmol/l in 3 months. The level of postprandial glycaemia decreased by 3.62 ± 1.09 mmol/l that in relative expression was –30.7 ± 10.2 % from the baseline. Conclusions. Taking into account the progressive nature of type 2 DM, glimepiride has advantages over gliclazide of prolonged action, when used in combination with metformin in antidiabetic therapy, especially in patients with long course of DM.

Keywords


type 2 diabetes mellitus; treatment; metformin; glimepiride

References


Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-79. doi: 10.2337/dc12-0413.

Abrahamson MJ. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? Yes, they continue to serve us well! Diabetes Care. 2015;38:160-169. doi: 10.2337/dc14-1945.

American Diabetes Association. Standards of Medical Care in Diabetes — 2017. Diabetes Care. 2017;40(1):1-132. doi: 10.2337/dc17-S003.

Inzucci SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140-9. doi: 10.2337/dc14-2441.

Pankiv VI. Individual system of treatment of type 2 diabetes mellitus: when, whom and what alternative variants, except metformin. Mezhdunarodnyi Endokrinologicheskii Zhurnal. 2013;8(56):36-9. (in Ukrainian).

Pareek A, Chandurkar NB, Salkar HR. et al. Evaluation of Efficacy and Tolerability of Glimepiride and Metformin Combination: A Multicentric Study in Patients with Type-2 Diabetes Mellitus, Uncontrolled on Monotherapy with Sulfonylurea or Metformin. American Journal of Therapeutics. 2013 Jan;20(1):41-7. doi: 10.1097/MJT.0b013e3181ff7c63.

Mokhort TV. Glimepiride is preparation of choice for treatment of type 2 diabetes mellitus. Lechebnoye delo. 2011;5(21):76-83. (in Russian).

Nakamura I, Oyama J-I, Komoda H, Shiraki A, et al. Possible effects of glimepiride beyond glycemic control in patients with type 2 diabetes: a preliminary report. Cardiovasc. Diabetol. 2014;13(15):1-8. doi: 10.1186%2F1475-2840-13-15.

Kravchun NA, Khyzhniak OO. Comparative analysis of application of glimepiride and prolonged action glyclazide in treatment of patients with type 2 diabetes mellitus. Problemy endokrynnoi patologii. 2010;1:5-11. (in Russian).

Charpentier G, Fleury F, Kabir M. et al. Improved glycaemic control by addition of glimepiride to metformin monotherapy in Type 2 diabetic patients. Diabetic Medicine. 2001 Oct;18(10):828-34. doi: 10.1046/j.1464-5491.2001.00582.x.

Ivko TI, Germaniuk TA. Mathematical design as method of choice pharmacoecononic reasonable chart of the combined therapy of type 2 diabetes mellitus. Klinichna farmatsiya. 2015;19(3):30-36.(in Ukrainian).

Poltorak VV, Krasova NS, Gorshunskaya MY. Combined therapy of Metformin and Glimepiride in patients with type 2 diabetes mellitus (molecular mechanisms of optimization of vindicatory action). Mezhdunarodnyi Endokrinologicheskii Zhurnal. 2015;1(65):87-97. (in Russian).

Tkachenko VI., Sadovnik YA. The features of sulfonylurea’s usе in the general practice: a systematic review of glimepiride researches. Liky Ukrainy. 2016;3(199):76-81. (in Ukrainian).

Korpacheva-Zinych OV, Lukashevych PY, Kushnareva NN, et al. Priority aspects of the glucose-lowering therapy in patients with type 2 diabetes: the interim results of the fist national multi-center study DіaDEYa (The study was conducted as part of the Ukrainian project to improve the quality of life in patients with type 2 diabetes mellitus). Endokrynologiya. 2016;21(4):287-302. (in Ukrainian).




DOI: https://doi.org/10.22141/2224-0721.13.2.2017.100598

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru